Moderna (MRNA): Why This Bear Still Growls, , on September 25, 2020 at 7:05 pm

By
On September 25, 2020
Tags:

It’s been a couple of week now since SVB Leerink analyst Mani Foroohar cited worries about increased competition in the CVOID-19 vaccine race (200 vaccines in process, dozens in clinical trials), and mRNA-1273 lost “lead in clinical development” in deciding to downgrade Moderna (MRNA) stock to “underperform.” A couple of weeks later… he’s still not optimistic.Foroohar explains that mRNA-1273 still appears like it will prove to be an effective vaccine against coronavirus. The FDA is looking for vaccines to prove 50% “vaccine efficacy” at a minimum before approving them for Emergency Use Authorization (EUA). mRNA-1273 looks likely to clear that bar easily, with efficacy percentages trending to exceed 60%, and perhaps rise as high as 75% or better “in a best case scenario.”How soon will we know for sure that mRNA-1273 makes the cut? Trial suspensions such as the one AstraZeneca suffered earlier this month when a patient in one of its Phase 3 trials suffered an adverse event could delay the process. But if all goes well, an initial “data readout” on the vaccine’s efficacy could still arrive as early as November, assuming Moderna follows FDA recommendations to track patient outcomes for at least two months after receiving their second inoculation.Of course, in addition to efficacy, there’s also “durability” to consider. Foroohar notes that it is currently unknown whether immunity to the novel coronavirus, conferred by mRNA-1273, will be permanent or require periodic booster shots. In Moderna’s opinion, notes the analyst, “there is reason to believe that … COVID-19 reinfection may happen somewhat frequently.” Recurrences may come with lower levels of intensity than in an initial infection, but even so, Moderna is anticipating that certain patients — “healthcare workers, elderly patients, those with respiratory issues or immune compromised, etc” — will require booster shots after initial inoculation “in the out years.”For patients hoping for a solution to coronavirus, this is certainly disappointing news, but for Moderna, the prospect of recurring booster shot revenues — perhaps years-worth of such revenues — to pay back its initial investment in developing mRNA-1273, would be a boon for the stock.Even if this is the way things play out, however, Foroohar still doesn’t think the stock is a “buy.”Why not? Although Foroohar gives mRNA-1273 a “high probability” of being eventually approved, the analyst’s worries about competing vaccines — Pfizer’s and Johnson & Johnson’s in particular — intruding upon Moderna’s market share continue to nag.On average, analysts following Moderna predict the company will do as much as $4.7 billion in sales next year, and perhaps $6.6 billion in 2022 — mostly from sales of mRNA-1273. At today’s prices, that works out to a 5.6 times forward sales valuation on Moderna stock (a 17% premium to Johnson & Johnson stock, for example, and a 37% premium to Pfizer). For the stock to rise much higher, Moderna would probably need to produce more sales. But “[we] don’t see a clear path to above-consensus sales in the first quarters of launch,” warns Foroohar.For that matter, even assuming a huge revenue windfall once the vaccine is approved, followed by recurring revenues thereafter, Foroohar says he can’t even see a clear path to Moderna even reaching, much less exceeding, consensus estimates “in the medium or long term even with rosy assumptions,” given the competition mRNA-1273 is likely to face.Simply put, therefore, as bright as Moderna’s prospects appear, they’re still not bright enough to justify the valuation — and so Foroohar is forced to conclude that this stock is a sell. The analyst maintained his bearish stance on MRNA with a $41 price target, which implies a 40% downside from current levels. (To watch Foroohar’s track record, click here)Other analysts might have to seriously disagree with Foroohar. The Street considers MRNA a Moderate Buy. According to TipRanks analytics, out of 14 analysts who cover the stock, 11 are bullish, 2 remain neutral, and only Foroohar is bearish. Meanwhile, the consensus price target stands at $91.86, showing a 32% upside from the current cost of a share. (See MRNA stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

Moderna (MRNA): Why This Bear Still GrowlsIt’s been a couple of week now since SVB Leerink analyst Mani Foroohar cited worries about increased competition in the CVOID-19 vaccine race (200 vaccines in process, dozens in clinical trials), and mRNA-1273 lost “lead in clinical development” in deciding to downgrade Moderna (MRNA) stock to “underperform.” A couple of weeks later… he’s still not optimistic.Foroohar explains that mRNA-1273 still appears like it will prove to be an effective vaccine against coronavirus. The FDA is looking for vaccines to prove 50% “vaccine efficacy” at a minimum before approving them for Emergency Use Authorization (EUA). mRNA-1273 looks likely to clear that bar easily, with efficacy percentages trending to exceed 60%, and perhaps rise as high as 75% or better “in a best case scenario.”How soon will we know for sure that mRNA-1273 makes the cut? Trial suspensions such as the one AstraZeneca suffered earlier this month when a patient in one of its Phase 3 trials suffered an adverse event could delay the process. But if all goes well, an initial “data readout” on the vaccine’s efficacy could still arrive as early as November, assuming Moderna follows FDA recommendations to track patient outcomes for at least two months after receiving their second inoculation.Of course, in addition to efficacy, there’s also “durability” to consider. Foroohar notes that it is currently unknown whether immunity to the novel coronavirus, conferred by mRNA-1273, will be permanent or require periodic booster shots. In Moderna’s opinion, notes the analyst, “there is reason to believe that … COVID-19 reinfection may happen somewhat frequently.” Recurrences may come with lower levels of intensity than in an initial infection, but even so, Moderna is anticipating that certain patients — “healthcare workers, elderly patients, those with respiratory issues or immune compromised, etc” — will require booster shots after initial inoculation “in the out years.”For patients hoping for a solution to coronavirus, this is certainly disappointing news, but for Moderna, the prospect of recurring booster shot revenues — perhaps years-worth of such revenues — to pay back its initial investment in developing mRNA-1273, would be a boon for the stock.Even if this is the way things play out, however, Foroohar still doesn’t think the stock is a “buy.”Why not? Although Foroohar gives mRNA-1273 a “high probability” of being eventually approved, the analyst’s worries about competing vaccines — Pfizer’s and Johnson & Johnson’s in particular — intruding upon Moderna’s market share continue to nag.On average, analysts following Moderna predict the company will do as much as $4.7 billion in sales next year, and perhaps $6.6 billion in 2022 — mostly from sales of mRNA-1273. At today’s prices, that works out to a 5.6 times forward sales valuation on Moderna stock (a 17% premium to Johnson & Johnson stock, for example, and a 37% premium to Pfizer). For the stock to rise much higher, Moderna would probably need to produce more sales. But “[we] don’t see a clear path to above-consensus sales in the first quarters of launch,” warns Foroohar.For that matter, even assuming a huge revenue windfall once the vaccine is approved, followed by recurring revenues thereafter, Foroohar says he can’t even see a clear path to Moderna even reaching, much less exceeding, consensus estimates “in the medium or long term even with rosy assumptions,” given the competition mRNA-1273 is likely to face.Simply put, therefore, as bright as Moderna’s prospects appear, they’re still not bright enough to justify the valuation — and so Foroohar is forced to conclude that this stock is a sell. The analyst maintained his bearish stance on MRNA with a $41 price target, which implies a 40% downside from current levels. (To watch Foroohar’s track record, click here)Other analysts might have to seriously disagree with Foroohar. The Street considers MRNA a Moderate Buy. According to TipRanks analytics, out of 14 analysts who cover the stock, 11 are bullish, 2 remain neutral, and only Foroohar is bearish. Meanwhile, the consensus price target stands at $91.86, showing a 32% upside from the current cost of a share. (See MRNA stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road
#12-01 Capital Tower
Singapore 068912

New York

Coming Soon!

Dubai

Coming Soon!

Market Coverage